Halozyme Therapeutics, Inc. HALO R3KPHARMA
Company Overview
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
Why Investors Should Care
Return on capital employed stands at 20.0%.
Net profit has compounded at 19.7% per year over the last five years.
Revenue has grown at a 33.5% CAGR over the past five years.
Maintains a net profit margin of 24.9%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $1.40B (+37.6% YoY); net profit $316.89M.
- Trailing 12 Months Year-on-year growth — revenue +47.7%, earnings +42.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 33.5%, profit CAGR 19.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 33.53% |
| 1 Year: | 47.70% |
Compounded Profit Growth
| 5 Years: | 19.68% |
| 1 Year: | 42.90% |
Stock Price Performance
| 1 Year: | +66.30% |
| 6 Months: | +58.95% |
| 3 Months: | +53.13% |
| 1 Month: | +5.03% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)66.17 · Neutral
P/E of 31.76 is above the sector median of 24.83 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 24.9%.
- Compounding revenue at 33.5% over 5 years.
- Profit CAGR of 19.7% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HALO Halozyme Therapeutics, Inc. R3KPHARMA | 108.31 | 31.76 | $12.29B | 0.00% | 19.97% | - | 33.53% | 19.68% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | 30.87M | 35.20M | 25.56M | - | 56.95M | 39.15M | 46.23M | - | 25.35M | 55.22M | 65.32M | - | 89.02M | 136.46M | 115.83M | 117.28M | 152.37M | 208.98M | 162.14M | 221.04M | 216.03M | 195.88M | 231.35M | 290.08M | 264.86M | 325.72M | 354.26M | 376.71M | 481.00M |
| Gross Profit | 5.39M | 4.20M | 5.42M | 5.18M | 5.39M | 4.20M | 5.42M | 3.89M | 4.99M | 5.26M | 5.11M | 3.75M | 3.65M | 5.64M | 5.06M | 3.74M | 3.88M | 6.87M | 6.01M | 2.36M | 597.00K | 3.48M | 6.18M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | 4.23M | -23.24M | - | -16.17M | -21.72M | -22.74M | - | -27.53M | -25.48M | 8.08M | - | -23.71M | -20.07M | -25.47M | - | 2.97M | -13.98M | -24.54M | - | -3.22M | 29.55M | 40.30M | - | 50.73M | 93.05M | 75.59M | 75.67M | 34.06M | 83.29M | 53.80M | 94.46M | 88.28M | 95.54M | 117.23M | 163.20M | 141.53M | 202.44M | 217.92M | 184.52M | 287.65M |
| Net Income | -26.88M | -28.95M | -27.39M | -19.82M | -26.88M | -28.95M | -27.39M | -32.90M | -30.76M | 2.75M | 123.88M | -27.46M | -22.89M | -27.85M | -2.13M | 1.80M | -14.62M | -25.02M | -34.40M | -6.10M | 25.82M | 36.21M | 73.16M | 27.89M | 91.46M | 216.59M | 60.11M | 22.68M | 61.63M | 39.62M | 74.75M | 81.84M | 76.82M | 93.25M | 137.01M | 118.09M | 165.16M | 175.22M | 150.05M | 229.91M |
| Diluted EPS | 0.02 | -0.19 | 0.03 | -0.12 | 0.02 | -0.23 | 0.03 | -260.00 | -230.00 | 20.00 | 850.00 | -0.19 | -0.16 | -0.19 | -0.01 | 0.01 | -0.10 | -0.17 | -0.24 | -0.04 | 0.19 | 0.25 | 0.50 | 0.19 | 0.62 | 1.48 | 0.43 | 0.16 | 0.44 | 0.29 | 0.56 | 0.61 | 0.60 | 0.72 | 1.05 | 0.93 | 1.33 | 1.43 | 1.22 | 1.90 |
| R&D Expense | 21.20M | 27.61M | - | 40.10M | 35.53M | 33.86M | - | 36.94M | 38.34M | 33.99M | - | 37.98M | 40.09M | 35.54M | - | 31.33M | 33.91M | 30.45M | - | 10.16M | 8.95M | 7.75M | - | 9.01M | 8.07M | 8.49M | 11.85M | 15.48M | 16.70M | 17.98M | 19.73M | 17.32M | 19.11M | 21.04M | 18.46M | 14.80M | 17.54M | 17.25M | 25.56M | 27.66M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.67M | 13.62M | 56.09M | 42.33M | 54.80M | 75.33M | 135.06M | 146.69M | 316.61M | 151.86M | 195.99M | 267.59M | 443.31M | 660.12M | 829.25M | 1.02B | 1.40B |
| Operating Income | -58.46M | -54.26M | -19.84M | -53.62M | -80.43M | -63.04M | -27.45M | -83.21M | 81.00M | -69.33M | -67.61M | 144.25M | 275.90M | 267.53M | 337.57M | 551.48M | 469.01M |
| Net Income | -58.36M | -53.24M | -19.77M | -53.55M | -83.48M | -68.38M | -32.23M | -103.02M | 62.97M | -80.33M | -72.24M | 129.09M | 402.71M | 202.13M | 281.59M | 444.09M | 316.89M |
| Diluted EPS | - | - | - | - | - | - | -0.25 | -0.81 | 0.45 | -0.56 | -0.50 | 0.91 | 2.74 | 1.44 | 2.10 | 3.43 | 2.56 |
| R&D Expense | 56.61M | 51.77M | 57.56M | 70.04M | 96.64M | 79.70M | 93.24M | 150.84M | 150.64M | 150.25M | 140.80M | 34.24M | 35.67M | 66.61M | 76.36M | 79.05M | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 91.35M | 65.76M | 134.73M | 101.79M | 165.98M | 181.79M | 261.51M | 519.95M | 440.25M | 565.87M | 579.92M | 1.10B | 1.84B | 1.73B | 2.06B | 2.53B |
| Total Equity | 15.38M | 6.90M | 20.35M | 10.90M | 48.85M | -19.99M | 41.35M | 43.00M | -32.48M | 208.37M | 248.89M | 91.77M | 151.05M | 196.95M | 169.80M | 83.81M | 363.82M | 48.81M |
| Cash & Equivalents | 63.72M | 67.46M | 82.76M | 52.38M | 99.50M | 27.36M | 61.39M | 43.29M | 66.76M | 168.74M | 57.94M | 120.18M | 147.70M | 118.72M | 234.19M | 118.37M | 115.85M | 133.82M |
| Long Term Debt | - | - | - | 0 | 29.66M | 49.77M | 49.86M | 27.97M | 199.23M | 125.14M | 34.87M | 383.05M | 0 | 787.25M | 1.49B | 1.50B | 1.51B | 2.14B |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.67B | 1.65B | 1.70B | 2.48B |
| Current Liabilities | - | - | 15.34M | 17.30M | 18.95M | 24.90M | 24.33M | 62.46M | 54.59M | 131.33M | 149.36M | 85.64M | 421.38M | 117.15M | 130.79M | 112.49M | 139.10M | 177.09M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -40.15M | -45.39M | -34.30M | -64.28M | -49.34M | -47.52M | -37.08M | -50.38M | 134.05M | -49.50M | -85.42M | 55.45M | 299.44M | 240.11M | 388.57M | 479.06M | 651.56M |
| Investing Cash Flow | -1.46M | -646.54K | -828.51K | -1.41M | -47.87M | -32.95M | 5.89M | -76.77M | -163.73M | 2.49M | -5.55M | 78.35M | -406.29M | -487.00M | -96.91M | -262.72M | -545.81M |
| Financing Cash Flow | 45.36M | 61.82M | 4.75M | 112.82M | 25.06M | 114.50M | 13.10M | 150.62M | 131.66M | -63.80M | 153.22M | -106.28M | 77.86M | 362.37M | -407.99M | -218.86M | -85.17M |
| Capital Expenditure | -1.46M | -646.54K | -828.51K | -1.41M | -2.30M | -1.37M | -2.36M | -3.14M | -1.35M | -4.66M | -4.04M | -2.50M | -1.46M | -4.81M | -15.29M | -10.70M | -6.97M |
| Free Cash Flow | -41.61M | -46.03M | -35.13M | -65.69M | -51.64M | -48.89M | -39.44M | -53.52M | 132.70M | -54.16M | -89.46M | 52.95M | 297.98M | 235.30M | 373.28M | 468.37M | 644.59M |
| Share Buybacks | - | - | - | - | - | - | - | - | 0 | 0 | 200.00M | 150.12M | 350.06M | 200.00M | 402.38M | 250.00M | 342.37M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -427.6% | -398.2% | -35.4% | -126.7% | -146.8% | -83.7% | -20.3% | -56.7% | 25.6% | -45.7% | -34.5% | 53.9% | 62.2% | 40.5% | 40.7% | 54.3% | 33.6% |
| Net Margin % | -426.9% | -390.8% | -35.2% | -126.5% | -152.3% | -90.8% | -23.9% | -70.2% | 19.9% | -52.9% | -36.9% | 48.2% | 90.8% | 30.6% | 34.0% | 43.7% | 22.7% |
| ROE % | -845.4% | -261.6% | -181.4% | -109.6% | 417.6% | -165.3% | -75.0% | 317.2% | 30.2% | -32.3% | -78.7% | 85.5% | 204.5% | 119.0% | 336.0% | 122.1% | 649.2% |
| ROCE % | - | -71.4% | -40.9% | -46.3% | -104.6% | -44.5% | -23.0% | -40.2% | 20.8% | -23.8% | -14.1% | 91.0% | 27.9% | 15.6% | 20.8% | 28.7% | 20.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 11.69% | 13.27M | $1.49B |
| 2 | Vanguard Capital Management LLC | 4.71% | 5.35M | $601.76M |
| 3 | Vanguard Portfolio Management LLC | 4.67% | 5.30M | $595.87M |
| 4 | State Street Corporation | 4.56% | 5.18M | $582.43M |
| 5 | Invesco Ltd. | 2.80% | 3.18M | $357.37M |
| 6 | Morgan Stanley | 2.50% | 2.83M | $318.53M |
| 7 | Boston Partners | 2.44% | 2.77M | $311.89M |
| 8 | Bank of America Corporation | 2.41% | 2.74M | $308.18M |
| 9 | Geode Capital Management, LLC | 2.22% | 2.52M | $283.37M |
| 10 | William Blair Investment Management, LLC | 2.21% | 2.51M | $282.37M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HALO
HALO Stock Rises 36% in a Month: Here's What You Should Know - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxOODY1UmpHRDlqcHh0eHVBSWFuQTYtZE9NYkdrUEZVQVVJZTNzRHFWUVR4aHNIbHpueEdTM0RtaWszUjRVUmhHX3FhajFMRjdyd0tBUmdScHBPLTBTcXF2SkNWTlllVGtVVTVqblNFT3ZieU5IT3JEaW5UUHJKME45aHd3QjhtSDJ2SVdpUE…
HALO Stocks in Emerging Markets Could Extend Rally as Heavy Industries Surge - Goldman Sachs
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNZXkxN3RtMENDVjUzaFBhSWc0LTk5MzJHZVBEVXNnVnlLajdkSlNsUlZUdGhpVTlYTWlkMUpvMWhBcjZ4Wk52dHNyUFl5N0xmWDV4aEw0cU83QXo3YVpWZFR4b1JBSUtBNmEteGJwSFlYZlpmUmE4eEowT2RxWUFOaVZYOWFELWhObWE5MW…
HALO stocks: AI-immune areas the pros are backing - Interactive Investor
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNSXNxR2p5elBjSHRYRXIyekJxZEJIYkVZTndXdmdUMGlaOERINHZ1YThPOXdGbU10RE91bDNyTHZuZXV2N2g3Rmt5WC03eHZQdmJweEIxSzNjTGgzbE9CeTRkT2hNWFowZEo2aEQ2aEtsNnBIT0NCTEktaW9rMFZBbTEtR25IRVRfV2gySz…
Our HALO Stock Swing Trade Featured An Angelic Exit - Investor's Business Daily
<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxOYTM5MjRBLVV5aURYWnlYSDA2dnRlSjhNbm1CNm41N0tOQzZPZXFsaXVVN0p2NVIzbzlNWk1IVHBEUXduREtuelB0QTNUYUpITUZfTlc4Z3NqZTYtSXJRUHZ5TFR4RWtVbW5lTHNKdjg5bUxZLUxtbnpBdFgxMWlNZg?oc=5" target="_…
Halozyme Therapeutics (NASDAQ:HALO) Beats Expectations in Strong Q2 CY2026, Guides for Strong Full-Year Sales - StockStory
<a href="https://news.google.com/rss/articles/CBMi9wFBVV95cUxNMEdOWnFmV2M0OGlTTkVBT2IwUHNSalZPSVdMNXBLUlFmMFB6MllwNksyUzVHbWdwT3FRSHFROWVTYWlIdG9nZEt2U2NZNzFTbVdlM3FLTVBFUWgwUGRWaklXeU9wVDJRSlRFb01Ua3JJM0tDb1ZLUWFlWHFidzhjOXpZQm9KaHdkZGRmMG…
Halozyme (HALO) Stock Could Be Fully Priced On The Board Appointment - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxOdm5xazFCY1ZwOHcxamJyYzZZdjJEUGRXZkV1cHZ2Tlc3ZE9hdTNxQjhCN0ZVelltY3pXa1NGOVhIZzNFd1AtVC1VZWxhZU5JelJTTGVhT1h1MUVGWUZDb09YdTRCODA2d0FlRllqLW1yQy1MaWlXcmVPXzQ0ZjFHaVBIVG5CQUpCY0s1dl…
HALO — Frequently Asked Questions
What is the current share price of Halozyme Therapeutics, Inc. (HALO)?
As of 2026-09-19 21:16 PDT, Halozyme Therapeutics, Inc. (HALO) trades at $108.31 on NasdaqGS. Its 52-week range is $61.63 to $110.76.
What is the market capitalisation of HALO?
Halozyme Therapeutics, Inc. (HALO) has a market capitalisation of $12.29B on NasdaqGS.
What is the P/E ratio of HALO?
HALO trades at a trailing price-to-earnings (P/E) ratio of 31.76. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 89.32.
Is HALO a good stock to buy?
This page provides a data-driven analysis of Halozyme Therapeutics, Inc. (HALO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.